NASDAQ:SRZN Surrozen (SRZN) Stock Price, News & Analysis $9.96 -0.52 (-4.96%) Closing price 05/2/2025 03:59 PM EasternExtended Trading$9.66 -0.30 (-2.96%) As of 05/2/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Surrozen Stock (NASDAQ:SRZN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Surrozen alerts:Sign Up Key Stats Today's Range$9.96▼$10.9550-Day Range$8.89▼$12.4552-Week Range$6.00▼$18.17Volume7,846 shsAverage Volume20,945 shsMarket Capitalization$32.68 millionP/E RatioN/ADividend YieldN/APrice Target$38.50Consensus RatingBuy Company OverviewSurrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.Read More… Surrozen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks76th Percentile Overall ScoreSRZN MarketRank™: Surrozen scored higher than 76% of companies evaluated by MarketBeat, and ranked 401st out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingSurrozen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSurrozen has only been the subject of 1 research reports in the past 90 days.Read more about Surrozen's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Surrozen are expected to decrease in the coming year, from ($8.49) to ($10.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Surrozen is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Surrozen is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSurrozen has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Surrozen's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.90% of the float of Surrozen has been sold short.Short Interest Ratio / Days to CoverSurrozen has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Surrozen has recently decreased by 26.08%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSurrozen does not currently pay a dividend.Dividend GrowthSurrozen does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.90% of the float of Surrozen has been sold short.Short Interest Ratio / Days to CoverSurrozen has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Surrozen has recently decreased by 26.08%, indicating that investor sentiment is improving significantly. News and Social Media2.2 / 5News SentimentN/A News SentimentSurrozen has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies. Company Ownership5.0 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Surrozen insiders have bought more of their company's stock than they have sold. Specifically, they have bought $11,999,991.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders45.18% of the stock of Surrozen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions66.57% of the stock of Surrozen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Surrozen's insider trading history. Receive SRZN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Surrozen and its competitors with MarketBeat's FREE daily newsletter. Email Address SRZN Stock News HeadlinesSurrozen files to sell 5.21M shares of common stock for holdersApril 25, 2025 | markets.businessinsider.comSurrozen reports FY24 EPS ($21.67) vs. ($21.33) last yearApril 2, 2025 | markets.businessinsider.comTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.May 3, 2025 | Porter & Company (Ad)Insiders Are Loving These 5 Tech and Biotech StocksApril 2, 2025 | 247wallst.comSurrozen Focuses on Ophthalmology Amid Financial ChallengesApril 2, 2025 | tipranks.comSurrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business UpdatesMarch 31, 2025 | globenewswire.comSurrozen to focus Wnt expertise, technologies on ophthalmology programsMarch 27, 2025 | markets.businessinsider.comSurrozen to discontinue development of SZN-043 in alcohol associated hepatitisMarch 26, 2025 | markets.businessinsider.comSee More Headlines SRZN Stock Analysis - Frequently Asked Questions How have SRZN shares performed this year? Surrozen's stock was trading at $14.35 at the beginning of 2025. Since then, SRZN shares have decreased by 30.6% and is now trading at $9.96. View the best growth stocks for 2025 here. How were Surrozen's earnings last quarter? Surrozen, Inc. (NASDAQ:SRZN) posted its quarterly earnings data on Monday, March, 31st. The company reported ($9.10) earnings per share for the quarter, missing the consensus estimate of ($2.54) by $6.56. The firm had revenue of $0.66 million for the quarter. When did Surrozen's stock split? Surrozen's stock reverse split on the morning of Thursday, December 14th 2023. The 1-15 reverse split was announced on Thursday, December 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Surrozen? Shares of SRZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Surrozen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Surrozen investors own include ACADIA Pharmaceuticals (ACAD), Marvell Technology (MRVL), HubSpot (HUBS), Avidity Biosciences (RNA), Adverum Biotechnologies (ADVM), Alpha and Omega Semiconductor (AOSL) and Company Calendar Last Earnings3/31/2025Today5/03/2025Next Earnings (Estimated)5/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SRZN CIK1824893 Webwww.consonancehfw.com Phone650-489-9000FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Stock Price Target$38.50 High Stock Price Target$45.00 Low Stock Price Target$32.00 Potential Upside/Downside+286.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($21.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-43,040,000.00 Net MarginsN/A Pretax Margin-444.38% Return on Equity-120.51% Return on Assets-54.68% Debt Debt-to-Equity RatioN/A Current Ratio7.40 Quick Ratio7.40 Sales & Book Value Annual Sales$10.66 million Price / Sales3.07 Cash FlowN/A Price / Cash FlowN/A Book Value$18.39 per share Price / Book0.54Miscellaneous Outstanding Shares3,281,000Free Float1,836,000Market Cap$32.68 million OptionableNot Optionable Beta0.69 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:SRZN) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Surrozen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Surrozen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.